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Table 1
Persistent BK
viremia n¼7
No persistent
viremia n¼65
P-value*
Age, years 6 (3-19) 8 (2-14) 0.57
Reduced intensity vs
myeloablative
71% 38% 0.12
Un-related donor
vs related
100% 71% 0.18
Fludarabine prep 86% 49% 0.11
Alemtuzumab prep 71% 37% 0.11
T-cell modulating
antibody
GVHD therapy
43% 12% 0.07
TMA 71% 37% 0.11
Pre-SCT nuclear GFR 111 (105-139) 122 (104-144) 0.64
Day 100 eGFR equations
CysC
Zappitelli 55 (42-64) 83 (62-103) 0.02
Rule 46 (35-55) 73 (53-93) 0.02
CKiD cysC 54 (44-62) 76 (60-90) 0.02
Creat
Bedside CKiD 104 (68-116) 100 (83-122) 0.86
CysC and creat
Full CKiD 68 (64-78) 89 (72-97) 0.06
Data as median (25th-75th percentile) or %.
GFR in ml/min/1.73m2, normal >90.
CKiD, Chronic Kidney Disease in Children study.
* Mann-Whitney U or Fischer exact.
Table 1
Reduce Intensity Conditioning for Marrow failure disorders
Characteristics Number (%)/
Median (range)
Total number of patients 22
Diagnosis
Shwachman-diamond syndrome 8
Aplastic anemia/marrow failure syndrome 7
Dyskeratosis Congenita 3
Seckel syndrome 1
Kostmann’s syndrome 1
Sideroblastic anemia 1
Congenital Macrothrombocytopenia 1
Age in years at HCT 7.27(0.7 -27)
Donor source
MSD 6
URD 15
UR cord 1
Stem cell source
Marrow 20
PBSC 1
Cord 1
Time to neutrophil engraftment (days) 12 (10-48)
Mixed chimerism 1
Resolved 1
GVHD
Acute GVHD (Gr II-III) 3
Chronic GVHD (skin) 3
Overall outcome
Alive 18
Deceased 4
Causes of and post-transplant day of death
Liver failure 668
Disseminated fungal infection 264
Coccidoidomycosis 35
Multiorgan failure 154
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adjusting for cidofovir.
Conclusions: T-cell modulating antibody therapy may be
a risk factor for BKV. pBKV possibly contributes to lower day
100 cysC eGFR, but we are unable to conclude an indepen-
dent association as most with pBVK also received nephro-
toxic cidofovir. Creat-based eGFR was no different, perhaps
because of low muscle mass after SCT. Future studies will
follow-up past day 100, temporally assess covariates (cido-
fovir), and uniformly measure BKV exposure in all subjects.
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Background: Hematopoietic cell transplantation (HCT)
remains the only potentially curative option for majority of
the inherited marrow failure syndromes and for patients
with aplastic anemia who don't respond to immune
suppression. It is challenging to rule out inherited marrow
failure syndromes with certainty in patients who present
with pancytopenia at very young age, with the possibility of
them carrying yet unidentiﬁed genetic mutation/s. This in
turn makes it difﬁcult to treat them similar to patients with
idiopathic aplastic anemia or using myeloablative prepara-
tive regimens/regimens containing total body irradiation(TBI). The inherent chemotherapy and radiation sensitivity of
some of the congenital marrow failure syndromes (e.g.
Shwachman-diamond syndrome (SDS), Dyskeratosis Con-
genita (DC)) leads to increased toxicity with intensive
conditioning regimens. Here we report our experience with
reduced intensity preparative regimen for Non-Fanconi
anemia marrow failure syndromes.
Methods: Total twenty two Non-FA marrow failure
syndromes and/or aplastic anemia patients were trans-
planted using a RIC regimen containing alemtuzumab, ﬂu-
darabine and Melphalan. Patients with Alemtuzumab doses
and schedules varied somewhat depending on size of the
patients (<10kg e got 0.2mg/kg/dose x 5 days) and on risk of
GVHD vs. mixed chimerism (alemtuzumab on days -22 to 18
vs from day -14 to 10). All patients received ﬂudarabine
30mg/M2 (1mg/kg if <10kg) on days -8 to -4, and melphalan
140mg/M2 (4.7mg/kg if <10kg) on day -3. Melphalan was
reduced by 50% in 3 patients with DC and 2 patients with
known chromosome sensitivity, due to concern for excessive
toxicity with full dose melphalan. GVHD prophylaxis con-
sisted of methylprednisolone and cyclosporine in all. Four-
teen patients additionally received methotrexate.
Results: Patient and transplant characteristics along with
results are shown in Table 1. Overall, one year probability of
survival was 84% with 95% conﬁdence interval of 67.0-100%.
This is a signiﬁcant improvement compared to historical
results. Eighteen patients are alive, well and remain 100%
engrafted at a median follow-up of 1.4 years (range 0.3-6.26).
Conclusion: We conclude that allogeneic HCT, using alem-
tuzumab, ﬂudarabine and melphalan-based reduced inten-
sity conditioning results in durable engraftment and an
excellent survival in pediatric patients with marrow failure
syndromes.
